95 results about "Hypertrophic cardiomyopathy" patented technology

Methods and systems for treating patients requiring tissue ablation for volumetric tissue reduction rely on the injection of ethanol and other tissue-ablating agents into the perivascular space surrounding body lumens, particularly blood vessels or vessels of the alimentary canal, reproductive system and urinary tract. Injection of tissue-ablating agents is intended treat conditions such as hypertrophic cardiomyopathy, benign and malignant tumors, benign prostatic hyperplasia, and uterine fibroids, for example. Injection may be achieved using intravascular catheters which advance needles radially outward from a body vessel lumen or by transmyocardial injection from an epicardial or endocardial surface of the heart.

A method for assisting in the diagnosis of heart murmurs. The method calculates a normalized measure of mid-range energy for at least one systolic or diastolic interval in a sequence of heartbeats and displays the mid-range energy measure of the systolic and / or diastolic interval in a graphical form. The sequence of heartbeats is also processed to detect and diagnose heart murmurs by adjusting a murmur count threshold responsive to the mid-range energy. The method may be used to diagnose hypertrophic cardiomyopathy and to determine effective therapeutic drug dosage or therapeutic device setting.

The invention provides application of a Trim63 gene in preparation of a high muscle content and hypertrophic cardiomyopathy model cloned pig. Somatic cells of the Trim63 gene of a modified pig are utilized as nuclear transfer donor cells, oocytes are utilized as nuclear transfer recipient cells, and a cloned embryo is obtained through the somatic cell nuclear transfer technology. The cloned embryo is transferred into a pig uterus to gestate to obtain the Trim63 gene modified high muscle content and hypertrophic cardiomyopathy model cloned pig, artificial intervention methods, such as operation and so on for the cloned pig are not needed any more, and the efficiency of establishment of a disease model is improved. According to the high muscle content and hypertrophic cardiomyopathy model cloned pig, paired Cas9n targeting vectors are utilized for the first time to perform gene editing for large animals. The method is low in cost, sharply shortens the time for obtaining a homozygote pig and lays a foundation for gene function research and the disease model establishment for the large animals by utilizing the CRISPR / Cas9 technology.

Disclosed herein are a collection of miRNAs and genes whose expression is altered in hypertrophic cardiomyopathy. Accordingly, these miRNAs and genes, singly or in combination, are useful as molecular markers for diagnosis or prognosis of hypertrophic cardiomyopathy. The miRNAs and genes disclosed can also be therapeutic targets for cardiac hypertrophy. For example, agents such as miRNA mimics, miRNA inhibitors or siRNAs for a given miRNA or gene can be used to modulate the level of these molecules thereby inhibiting or preventing hypertrophic cardiomyopathy.

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and / or Ca2+- sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and / or Ca2+-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.

The invention relates to the technical field of biology and particularly relates to a non-treatment-purpose method for screening mutation of pathogenic genes relevant with hypertrophic cardiac myopathy. The method comprises the following steps: (1) extracting genomes; (2) carrying out multiplex PCR amplification on target genes; (3) constructing a target gene library; and (4) sequencing the target gene library by virtue of a next-generation semiconductor sequencing platform, and screening gene mutation sites relevant with the hypertrophic cardiac myopathy. The method is simple, convenient, rapid and low in cost, multiple samples can be detected once, the foundation is laid for the screening of the hypertrophic cardiac myopathy, and the road is exploited for the clinic molecular diagnosis.

The invention provides an ablation needle component and an ablation system. The ablation needle component comprises a hollow outer sleeve and an ablation needle, wherein the outer sleeve movably sleeves outside an electrode needle main body of the ablation needle and is connected with an ablation handle in a detached and rotating manner, so that the ablation needle can be separated from the outersleeve after an ablation operation is completed, the outer sleeve is still kept in a tissue, a channel is provided for other operations, such as biopsy, repeated puncture is avoided, damages on tissues are reduced, and the biopsy operation can be convenient and efficient. Furthermore, the ablation handle is in rotating connection with the outer sleeve, the electrode needle main body can be drivento rotate relative to the outer sleeve when the ablation handle rotates relative to the outer sleeve, which means that the outer sleeve and the electrode needle main body are not of an integral structure, and the outer sleeve can be kept standing still when the ablation needle should be rotated, so that damages on tissues can be reduced, and the rotating resistance is relatively small. Therefore,the ablation needle component and the ablation system are especially applicable to radiofrequency ablation treatment of hypertrophic cardiomyopathy.

The present invention discloses a crystalline ARB-NEPi dicationic compound and a preparation method and application thereof. In particular, the present invention relates to the crystalline ARB-NEPi dicationic compound having the formula of NEPi.Nax.Ky.ARB.ZH2O. The present invention also relates to a pharmaceutical composition containing an effective amount of the crystalline dicationic compound and application of the pharmaceutical composition in the preparation of drugs for treatment or prevention of neutral-endopeptidase-related diseases, cardiovascular diseases, hypertension, acute and chronic heart failures, congestive heart failure, left ventricular dysfunction, hypertrophic cardiomyopathy, diabetic cardiomyopathy, supraventricular arrhythmia and ventricular arrhythmia, atrial fibrillation, atrial flutter or detrimental vascular remodeling, and the like, and the pharmaceutical composition has broad application prospects.

The invention discloses a DNA library for detection of hereditary cardiomyopathy causing gene mutation through the targeting high-flux semiconductor sequencing technology and application thereof. Specifically, a primer pool is designed according to 80 hereditary cardiomyopathy causing genes, super-multiple PCR amplification is performed on sample genome DNA, and an amplified product is sequenced through the high-flux semiconductor sequencing technology to find pathogenic mutation so as to provide genetic and molecular biological theoretical bases for clinical diagnosis. The DNA library has the advantages of being accurate, quick, flexible and low in cost; through 80 gene detection areas related to the DNA library, five kinds of common hereditary cardiomyopathy including hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy and left ventricular myocardial densification incomplete cardiomyopathy can be detected, and the DNA library has an important meaning and clinical value for diagnosis and differential diagnosis of the hereditary cardiomyopathy.

The invention relates a pharmaceutical composition comprising a combination of:(i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction, such as Alzheimer's, glaucoma and stroke, comprising administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need thereof.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a MYH7 allele comprising a disease-associated mutation, e.g., for the treatment of hypertrophic cardiomyopathy. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

The invention relates to several new mutations of pathogenic genes for hypertrophic cardiomyopathy, and their use in the treatment and diagnosis of hypertrophic cardiomyopathy.

Genomically modified livestock animals having a modification in one or more genes implicated in heart failure are provided. The animals provide models for various pathologies in heart failure including dilated cardiomyopathy and hypertrophic cardiomyopathy and can be used for investigation of new treatment methods including interventional devices, biologics and pharmaceuticals. The models can also be induced to develop metabolic syndrome (MetS) and are therefore amenable to further investigation of the confounding effects of MetS on the progress of heart failure.

The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HCM. The invention further relates to a treatment programme for treating HCM, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HCM or the symptoms thereof.

The invention pertains to methods for detecting the presence or absence of a mutation associated with hypertrophic cardiomyopathy (HC). The methods include providing DNA which encodes a cardiac myosin binding protein and detecting the presence or absence of a mutation in the amplified product which is associated with HC. The invention further pertains to methods for diagnosing HC in a subject. These methods typically include obtaining a sample of DNA which encodes a cardiac myosin binding protein from a subject being tested for FHC and diagnosing the subject for FHC by detecting the presence or absence of a mutation in the sarcomeric thin filament protein which causes FHC as an indication of the disease. Other aspects of the invention include kits useful for diagnosing HC and methods for treating HC.

The invention belongs to the traditional Chinese pharmaceutics field, and relates to an application of traditional Chinese medicine radix scrophulariae to the preparation of a drug for preventing and curing cardiac hypertrophy, hypertrophic cardiomyopathy and chronic heart failure. The invention researches the effect of the cardiac hypertrophy and ventricle reconstruction model of a plurality of mice and rats on the traditional Chinese medicine radix scrophulariae. The experimental results show that the radix scrophulariae water or the alcohol abstracts has evident function for preventing the cardiac hypertrophy, the ventricular remodeling and the chronic heart failure caused by various reasons, the mechanism is obviously related with the excessive activation of the neuroendocrine system such as a suppressing renin-angiotensin-aldosterone system and is related with the functions of blood pressure reduction, heart beat slowing and hemodynamics improvement. The figwort can be used for preparing the drug for preventing the diseases of cardiac hypertrophy, hypertrophic cardiomyopathy and chronic heart failure and for reducing the possibility of the incidence rate of arrhythmia and the sudden death of patients with cardiac hypertrophy, hypertrophic cardiomyopathy and chronic heart failure.

The present invention provides novel bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HCM. The invention further relates to a treatment programme for treating HCM, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HCM or the symptoms thereof.

A method and device for the treatment of hypertrophic cardiomyopathy. The device includes a cutting device for resection of a thickened myocardium. The operator positions the cutting device adjacent to the myocardium that is to be resected and then slides a tubular blade within an outer shell of the cutting device to resect the septum.

The invention pertains to methods for detecting the presence or absence of a mutation associated with hypertrophic cardiomyopathy in cats, particularly domesticated cats, and more particularly Maine Coon cats. The methods include detecting the presence or absence of a mutation in the feline MYBPC gene, and identifying feline subjects that have or are at risk of developing hypertrophic cardiomyopathy.

The invention relates to the technical field of biology, in particular relates to medical molecular diagnosis and biotechnology, and specifically relates to a primer group and applications of the primer group. A primer combination comprises at least one group of five groups of real-time fluorescent PCR primers capable of detecting five hotspot mutation sites including MYH7-c.1987C>T, TNNI3-c.370G>C, MYH7-c2155C>T, TNNI3-c.433C>G and PRKAG2-c.298G>A, and Taqman-MGB probe sequences. The primer combination can detect a plurality of case samples at one time, also can realize the combined detection of five mutation sites on each sample, and has the features of being simple and convenient, rapid, accurate and economical, and thus a novel method is established for the clinical early molecular diagnosis and prevention of hypertrophic cardiomyopathy.

This invention provides a system and a method for monitoring a patient's Formation number (Fn) and comparing the measured Fn to the baseline data of healthy persons population or to the patient's past history data to assess the degree of ventricular and / or valvular dysfunction, wherein the valvular dysfunction may comprise dilated cardiomyopathy, hypertrophic cardiomyopathy, ischemic cardiomyopathy, restrictive cardiomyopathy, or the like.

The invention belongs to the technical field of biology, relates to medical molecular diagnosis and biotechnology and relates to a primer composition, a kit composed of the primer composition and application. The primer composition comprises a real-time fluorescence PCR (Polymerase Chain Reaction) primer for detecting a new mutation site c.622 greater than G of a TAZ gene and a Taqman-MGB (Minor Groove Binder) probe sequence. The primer composition can be used for detecting a plurality of case samples and has the characteristics of simplicity, rapidness, accuracy and economical efficiency and the like; a new method is established for clinical early-stage molecular diagnosis and prevention of hypertrophic cardiomyopathy.

The invention discloses a construction method of a gene detection library of hereditary hypertrophic cardiomyopathy and a kit and relates to mutation of ACTC1, ACTN2, MYBPC3, MYH7, MYL2, MYL3, TNNI3,TNNT2 and TPM1 genes. Target regions comprise an exon region of coding amino acid of the 9 genes and 20 basic group regions at the upstream and downstream of an exon; in order to ensure that all the target regions are covered, a target region library is obtained through a hybridization probe capturing method after the library is prepared; then an LMPCR (Ligation-Mediated Polymerase Chain Reaction)method is adopted to amplify the library; and after the library is purified, a sample library for sequencing is obtained. The library construction method has simple steps and a rapid speed and the cost of constructing the library is effectively reduced; related genes of the hypertrophic cardiomyopathy are covered; an illumina high-throughput sequencing machine is combined and related gene mutation can be rapidly and accurately obtained; and the construction method has great significance on the hereditary hypertrophic cardiomyopathy.

The invention discloses a deuterated benzylaminopyrimidine dione derivative and an application thereof, and a pharmaceutical composition containing the deuterated benzylaminopyrimidine dione derivative, and the deuterated benzylaminopyrimidine dione derivative and the pharmaceutical composition can be used for inhibiting the activity of myosin. The invention also relates to a method for preparingthe compound and the pharmaceutical composition, and an application of the compound and the pharmaceutical composition in treating hypertrophic cardiomyopathy and related heart diseases.

The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In some embodiments, the GPCR is mammalian, preferably human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gq. In some embodiments, the GPCR increases the intracellular level of inositol 1,4,5-triphosphate (IP3). In some embodiments, a modulator of the GPCR is a modulator of cardiomyocyte hypertrophy. The present invention further relates to methods of using a modulator of the GPCR. Preferred modulators are inverse agonists and antagonists. Inverse agonists and antagonists of the invention are useful as therapeutic agents for the prevention or treatment of heart disease, including hypertrophic cardiomyopathy and congestive heart failure, in particular hypertrophic cardiomyopathy resulting from post-myocardial infarction remodeling, cardiac valve disease, sustained cardiac afterload, myocarditis, and familial hypertrophic cardiomyopathy.

The invention provides a melting needle assembly and a melting system. The melting needle assembly comprises a hollow insulating sleeve pipe and a melting needle, wherein an electrode needle main bodyof the melting needle is movably mounted in the insulating sleeve pipe in a penetrating manner; the far end part of the electrode needle main body is provided with a first main bevel; the near end and the far end of the first main bevel are respectively located on two opposite sides of an axis of the electrode needle main body; the distance between the near end of the first main bevel and the axis of the electrode needle main body is greater than or equal to that between the far end of the first main bevel and the axis of the electrode needle main body; and the inclined angle between the first main bevel and the axis of the electrode needle main body is in the range of 15-60 degrees, so that the melting region of the far end part of the electrode needle main body is not globular or subglobular, but adopts an irregular shape which is deflected facing the opposite side of the first main bevel, the maximum width of the melting region is reduced to be adapted to a flat ventricle intervalstructure, the situation that the melting needle assembly penetrates through to an endocardium is avoided; and the melting needle assembly is especially suitable for radio frequency melting treatmentof the hypertrophic cardiomyopathy.